Skip to main content
  • Register
  • Help
  • Contact us

Auris Medical Holding Ltd (EARS) Ordinary Shares

Sell:$3.18 Buy:$3.19 Change: $0.48 (16.55%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$3.18
Buy:$3.19
Change: $0.48 (16.55%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$3.18
Buy:$3.19
Change: $0.48 (16.55%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.

Contact details

Address:
Bahnhofstrasse 21
ZUG
6300
Switzerland
Telephone:
+41 (61) 2011350
Website:
https://aurismedical.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EARS
ISIN:
BMG070252017
Market cap:
$37.32 million
Shares in issue:
12.87 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Bermuda
Currency:
US dollar
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.